Bioasis is breaking down a literal barrier to better neurological disease treatments
b'
Deborah Rathjen, Executive Chair of Bioasis Technologies Inc. (TSXV: BTI | OTCQB: BIOAF), highlights the company\\u2019s xB3 platform which is being developed to treat patients who suffer from a variety of central nervous system disorders.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3\\u2122 platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.